Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Crizotinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 50 Lymphoid 11 Plasma cell 8 Tumor-Agnostic 6 CNS 6 Gastrointestinal 5 Genitourinary 4 Other hematologic neoplasm 2 Dermatologic 2 Sarcoma 1 Other solid neoplasm 1 Gynecologic 1 Endocrine 1 Breast 1

Conditions

Neoplasm Metastasis 1 Breast Neoplasms 1

Interventions

Trastuzumab 607 Paclitaxel 565 Cyclophosphamide 543 Docetaxel 479 Capecitabine 419 Letrozole 359 Fulvestrant 325 Carboplatin 317 Doxorubicin 284 Tamoxifen 257 Anastrozole 227 pembrolizumab 222 exemestane 211 Radiotherapy 211 Epirubicin 203 Bevacizumab 188 pertuzumab 186 palbociclib 173 Gemcitabine 172 Vinorelbine 169 Lapatinib 157 Magnetic Resonance Spectroscopy 145 130-nm albumin-bound paclitaxel 140 eribulin 132 Surveys and Questionnaires 129 Albumin-Bound Paclitaxel 129 Exercise 122 Fluorouracil 111 Drug Therapy 109 Blood Specimen Collection 105

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡